Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Fundamental Analysis

NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD

248.31  -0.92 (-0.37%)

Fundamental Rating

3

Taking everything into account, ALNY scores 3 out of 10 in our fundamental rating. ALNY was compared to 571 industry peers in the Biotechnology industry. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNY is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALNY had negative earnings in the past year.
In the past year ALNY has reported a negative cash flow from operations.
In the past 5 years ALNY always reported negative net income.
In the past 5 years ALNY reported 4 times negative operating cash flow.
ALNY Yearly Net Income VS EBIT VS OCF VS FCFALNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

1.2 Ratios

ALNY has a better Return On Assets (-6.56%) than 88.79% of its industry peers.
ALNY has a worse Return On Equity (-414.62%) than 76.88% of its industry peers.
Industry RankSector Rank
ROA -6.56%
ROE -414.62%
ROIC N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNY Yearly ROA, ROE, ROICALNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

ALNY's Gross Margin of 85.62% is amongst the best of the industry. ALNY outperforms 89.14% of its industry peers.
ALNY's Gross Margin has been stable in the last couple of years.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
ALNY Yearly Profit, Operating, Gross MarginsALNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNY has been increased compared to 1 year ago.
Compared to 5 years ago, ALNY has more shares outstanding
ALNY has a better debt/assets ratio than last year.
ALNY Yearly Shares OutstandingALNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALNY Yearly Total Debt VS Total AssetsALNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

ALNY has an Altman-Z score of 3.21. This indicates that ALNY is financially healthy and has little risk of bankruptcy at the moment.
ALNY has a better Altman-Z score (3.21) than 77.41% of its industry peers.
A Debt/Equity ratio of 15.27 is on the high side and indicates that ALNY has dependencies on debt financing.
With a Debt to Equity ratio value of 15.27, ALNY is not doing good in the industry: 84.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 15.27
Debt/FCF N/A
Altman-Z 3.21
ROIC/WACCN/A
WACC9.16%
ALNY Yearly LT Debt VS Equity VS FCFALNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

ALNY has a Current Ratio of 2.78. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY's Current ratio of 2.78 is on the low side compared to the rest of the industry. ALNY is outperformed by 67.43% of its industry peers.
ALNY has a Quick Ratio of 2.71. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.71, ALNY is not doing good in the industry: 66.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.71
ALNY Yearly Current Assets VS Current LiabilitesALNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

ALNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.04%, which is quite impressive.
Looking at the last year, ALNY shows a very strong growth in Revenue. The Revenue has grown by 22.97%.
Measured over the past years, ALNY shows a very strong growth in Revenue. The Revenue has been growing by 59.21% on average per year.
EPS 1Y (TTM)39.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%34.9%

3.2 Future

The Earnings Per Share is expected to grow by 61.86% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 23.94% on average per year.
EPS Next Y22.85%
EPS Next 2Y57.33%
EPS Next 3Y63.05%
EPS Next 5Y61.86%
Revenue Next Year27.01%
Revenue Next 2Y26.43%
Revenue Next 3Y26.61%
Revenue Next 5Y23.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNY Price Earnings VS Forward Price EarningsALNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNY Per share dataALNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

ALNY's earnings are expected to grow with 63.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.33%
EPS Next 3Y63.05%

More info and screens

0

5. Dividend

5.1 Amount

ALNY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (3/6/2025, 12:10:38 PM)

248.31

-0.92 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners96.57%
Inst Owner Change4.35%
Ins Owners0.38%
Ins Owner Change3.15%
Market Cap32.03B
Analysts77.84
Price Target311.37 (25.4%)
Short Float %2.6%
Short Ratio4.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.9%
Min EPS beat(2)-2.21%
Max EPS beat(2)4%
EPS beat(4)3
Avg EPS beat(4)36.72%
Min EPS beat(4)-2.21%
Max EPS beat(4)88.19%
EPS beat(8)6
Avg EPS beat(8)39.21%
EPS beat(12)7
Avg EPS beat(12)19.17%
EPS beat(16)9
Avg EPS beat(16)12.2%
Revenue beat(2)0
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-7.88%
Max Revenue beat(2)-0.39%
Revenue beat(4)2
Avg Revenue beat(4)12.7%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)45.66%
Revenue beat(8)4
Avg Revenue beat(8)16.17%
Revenue beat(12)5
Avg Revenue beat(12)7.93%
Revenue beat(16)8
Avg Revenue beat(16)6.44%
PT rev (1m)0.19%
PT rev (3m)0.79%
EPS NQ rev (1m)-34.61%
EPS NQ rev (3m)-54.26%
EPS NY rev (1m)-62.3%
EPS NY rev (3m)-36.82%
Revenue NQ rev (1m)7.03%
Revenue NQ rev (3m)6.04%
Revenue NY rev (1m)5.88%
Revenue NY rev (3m)7.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.25
P/FCF N/A
P/OCF N/A
P/B 477.39
P/tB 477.39
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS17.43
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.56%
ROE -414.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.62%
FCFM N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 15.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.49%
Cap/Sales 1.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.71
Altman-Z 3.21
F-Score5
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
EPS Next Y22.85%
EPS Next 2Y57.33%
EPS Next 3Y63.05%
EPS Next 5Y61.86%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%34.9%
Revenue Next Year27.01%
Revenue Next 2Y26.43%
Revenue Next 3Y26.61%
Revenue Next 5Y23.94%
EBIT growth 1Y37.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year250%
EBIT Next 3Y188.84%
EBIT Next 5Y116.85%
FCF growth 1Y-201.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.98%
OCF growth 3YN/A
OCF growth 5YN/A